Clinicopathological significance of 5′-3′ exoribonuclease 2 expression in small cell lung cancer tissues

Abstract Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy. Overall survival in SCLC patients remains poor, and there is a lack of treatment options after the failure of first-line therapy. 5′-3′ exoribonuclease 2 (XRN2) is associated with tumor progression. However, its mechanism in SCLC remains unclear. In this study, we collected and analyzed the expression data for XRN2 mRNA in SCLC and non-cancer lung tissues, as well as pan-cancer and non-cancer tissues from high-throughput datasets and identified XRN2